Takinib belongs to the aminobenzimidazole class of inhibitors. Takinib (EDHS-206) 是一种有效且选择性的 TAK1 抑制剂 (IC50=9.5 nM),比 IRAK4 (IC50=120 nM) 和 IRAK1 (IC50=390 nM) 作用强 1.5 log 倍。Takinib 是一种TAK1自磷酸化的抑制剂,在 ATP 结合口袋内非竞争性结合。在类风湿关节炎和转移性乳腺癌细胞模型中,Takinib 诱导 TNF-α 刺激的细胞凋亡 (apoptosis)。Takinib 也是恶性疟原虫蛋白激酶 9 (PfPK9) 的抑制剂 (KD(app) of 0.46 nM)。
Application
Takinib has been used as an inhibitor of transforming 28 growth factor - β-activated kinase -1 (TAK-1) in human leukemia monocytic THP-1 cells. It may be used as a TAK1 inhibitor in Jurkat cells.
有力和选择性的TAK1 / MAP3K7激酶抑制剂(IC50 = 8.2-9.5 nM)。对IRAK4,IRAK1,GCK,CLK2和MINK1的TAK1选择性(IC50值分别为120、390、430、430和1900 nM)。在Src和Yes1处显示弱抑制。不抑制MAP2K或其他MAP3K家族成员。在类风湿关节炎和转移性乳腺癌的体外模型中,在TNF-α刺激后诱导细胞凋亡。
Takinib is a selective inhibitor of TAK1/MAP3K7 kinase, which is a member of the MAP3K family and a key regulator of cell death. It binds in the TAk1 ATPbinding pocket with an IC50 value of 9.5 nM. Takinib selectively induced apoptosis following TNF-α stimulation in rheumatoid arthritis and breast cancer.